CTOs on the Move

Avrobio

www.avrobio.com

 
AVROBIO`s vision is to bring personalized gene therapy to the world. We aim to prevent, halt or reverse disease throughout the body with a single dose of gene therapy designed to drive durable expression of therapeutic protein, even in hard-to-reach tissues and organs including brain, muscle and bone. Our ex vivo lentiviral gene therapy pipeline includes clinical programs in Fabry disease, Gaucher disease type 1 and cystinosis, as well as preclinical programs in Hunter syndrome, Gaucher disease type 3 and Pompe disease. AVROBIO is powered by our industry leading plato® gene therapy platform, our foundation designed to deliver gene therapy ...
  • Number of Employees: 100-250
  • Annual Revenue: $10-50 Million
  • www.avrobio.com
  • One Kendall Square Building 300, Suite 201
    Cambridge, MA USA 02139
  • Phone: 617.914.8420

Executives

Name Title Contact Details
Kim Raineri
Chief Manufacturing and Technology Officer Profile
Kim Raineri
Chief Manufacturing and Technical Operations Officer Profile

Funding

Avrobio raised $25M on 08/03/2016
Avrobio raised $60M on 02/01/2018

Similar Companies

Rebus Biosystems

Advanced imaging, fluidics, chemistry and bioinformatics. Innovative, robust tools for spatial omics without compromise. Rebus Esper platform available now.

BioShield Technologies

BioShield Technologies is a Norcross, GA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Cyagra Inc

Cyagra Inc is a Elizabethtown, PA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Merrimack Pharmaceuticals

Merrimack is a biopharmaceutical company discovering, developing and preparing to commercialize innovative medicines paired with companion diagnostics for the treatment of cancer. Merrimack seeks to gain a deeper understanding of underlying cancer biology through its systems biology-based approach and develop new insights, therapeutics and diagnostics to improve outcomes for cancer patients. Merrimack has multiple oncology therapeutics in clinical development and additional candidates in late stage preclinical development. Merrimack has a New Drug Application under review for its lead product candidate, MM-398, for the treatment of patients with metastatic adenocarcinoma of the pancreas who have been previously treated with gemcitabine-based therapy.

Roivant

Roivant Sciences is a global healthcare company focused on realizing the full value of promising biomedical research to improve the lives of patients and their families. Roivant`s mission is to reduce the time and cost of developing new medicines for patients and to share those savings with the broader healthcare system. Roivant is a unique biopharmaceutical company with world-class drug development experts working across multiple clinical and functional areas. We deliver R&D solutions to our partners in the biopharmaceutical industry, helping them unlock value from their pipelines by completing the clinical development of promising drug candidates. Our pipeline spans multiple therapeutic areas through partnerships with academic institutions and pharmaceutical companies, including Takeda, Merck, GlaxoSmithKline, Vertex, Eisai, Arena Pharmaceuticals, Portola Pharmaceutcals, Duke University, and Cincinnati Children`s Hospital Medical Center.